세계의 알파1 항트립신 결핍 질환 시장 - 산업 규모, 점유율, 동향, 기회, 예측(2018-2028년) : 제품별, 투여 경로별, 유통 채널별, 지역별, 경쟁사별

Alpha-1 Antitrypsin Deficiency Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Route Of Administration, By Distribution Channel, By Region, By Competition.

US $ 4,500 ￦ 6,356,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,768,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,300,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

알파1 항트립신 결핍 질환 세계 시장은 2022년 18억 936만 달러에 달했고, 예측 기간 동안 연평균 성장률(CAGR) 6.49%로 성장하여 2028년까지 26억 2,718만 달러에 달할 것으로 전망됩니다.

알파1 항트립신 결핍 질환은 폐와 간에 영향을 미치는 희귀한 유전성 질환으로, α1 항트립신 단백질의 양이 충분하지 않아 폐와 간 질환에 대한 취약성이 높아지는 질환입니다. 희귀질환임에도 불구하고 알파1 항트립신 결핍증은 환자의 삶의 질과 의료 시스템에 큰 영향을 미칩니다. 연구가 진행되고 인지도가 높아짐에 따라 α1 항트립신 결핍증 시장은 변화하고 있으며, 이는 도전과 기회로 작용하고 있습니다.

α1 항트립신은 간에서 생산되는 단백질로 효소에 의한 염증 유발 손상으로부터 폐를 보호하는 데 매우 중요하며, α1 항트립신 결핍증의 경우 유전자 변이로 인해 잘못 접힌 단백질이 혈류로 방출되지 않고 간에서 축적됩니다. 이 결핍증은 만성폐쇄성폐질환(COPD)과 같은 폐질환과 간경변과 같은 간질환에 대한 감수성을 높입니다.

시장 개요
예측 기간	2024년-2028년
2022년 시장 규모	18억 936만 달러
2028년 시장 규모	26억 2,718만 달러
CAGR 2023-2028년	6.49%
급성장 부문	α1 프로테이나제 억제제
최대 시장	북미

정부의 이니셔티브와 연구 자금으로 세계 α1 항트립신 결핍증 시장 견인 α1 항트립신 결핍증과 같은 희귀질환에 대한 인식이 높아짐에 따라 연구, 진단 및 치료법 개발을 지원하는 정책 및 프로그램이 주도하고 있습니다. 연구 프로젝트, 임상시험, 환자 지원을 위한 자금이 제약회사와 연구자들을 끌어들이면서 가속도가 붙고 있습니다.

주요 시장 성장 촉진요인

• 1.환자 수 증가: α1 항트립신 결핍증 세계 시장은 환자 수 증가로 인해 크게 성장하고 있습니다. 희귀한 유전성 질환이지만, 인지도가 높아지고 진단의 정확도가 높아짐에 따라 과소 보고된 사례와 오진으로 인해 대상 환자 수가 증가하고 있습니다. 환자 수가 증가함에 따라 제약 및 연구에 대한 관심이 높아져 시장 확대의 원동력이 되고 있습니다.
• 2.규제 당국의 지원: 연구자, 임상의, 환자, 옹호 단체 및 제약사의 협력은 α1 항트립신 결핍증에 대한 이해, 치료 및 환자 치료의 진전을 촉진합니다. 연구기관 간 컨소시엄, 제약회사와 대학 간 공동연구, 디지털 데이터 공유는 전통적인 연구 및 치료 접근 방식을 변화시키고 발전을 촉진할 것입니다.

주요 시장 과제

• 1. 과소 진단 및 오진: α1 항트립신 결핍증 시장의 가장 큰 도전은 과소 진단과 오진입니다. 많은 환자들이 진단을 받지 못하거나 다른 폐 질환으로 오진되어 정확한 치료 전략이 늦어지고 있습니다.
• 2.인식 부족: α1 항트립신 결핍증은 희귀질환이기 때문에 일반 대중과 의료 전문가들의 인식이 낮아 진단이 늦어지고 지원이 부족합니다.
• 3.복잡한 치료법: α1 항트립신 결핍증은 유전적 특성과 폐와 간의 이중 합병증으로 인해 효과적인 치료법 개발이 복잡하고 두 가지 측면을 모두 충족하는 치료법이 필요합니다.

주요 시장 동향

• 1.기술의 발전: 유전자 검사의 기술 발전으로 α1 항트립신 결핍증을 조기에 발견할 수 있게 되어 적극적인 개입이 가능해졌습니다. 정밀의학은 유전적 체질에 따라 치료를 조정하여 효과를 높일 수 있습니다. 유전자 치료와 유전자 편집은 유전자의 근원을 치료하는 것을 추구하며 질병 관리를 혁신적으로 바꿀 수 있습니다.
• 2.공동연구: 다학제간 공동연구를 통해 α1 항트립신 결핍증에 대한 이해와 관리를 가속화합니다. 연구 컨소시엄, 제약회사와 학계 파트너십, 환자 지원 단체는 연구, 기술 혁신, 치료법 개발을 촉진합니다.

부문별 인사이트

• 1.제품 2022년, α1 단백질 분해효소 억제제 부문은 α1 항트립신 결핍증 시장을 주도할 것으로 예상되며, 향후에도 성장 궤도를 유지할 것으로 예상됩니다. 효소대체요법(ERT)을 통해 부족한 A1PI 수치를 보충하여 증상을 완화하고 폐 손상의 진행을 지연시킬 수 있습니다.
• 2.유통 채널: 알파1 항트립신 결핍증 환자가 필요로 하는 다양한 분야의 전문가가 참여하는 종합적인 치료로 인해 병원 약국이 2022년 시장을 독점할 것으로 예상됩니다.

지역별 인사이트

북미:연구의 중심지인 북미는 알파1 항트립신 결핍증에 대한 이해, 진단 및 치료를 촉진하는 주요 기관, 연구센터 및 제약회사를 보유하고 있습니다. 임상시험은 주로 이 지역에서 진행되어 새로운 치료법에 대한 조기 접근을 가능하게 하고 북미 시장에서의 리더십을 확고히 하고 있습니다. 이 지역의 가처분 소득, 의료 지출 및 보험 적용 범위가 시장 지배력을 높이고 있습니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 알파1 항트립신 결핍 질환 세계 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별(α1 프로테이나제 저해제, 기관지 확장제, 부신피질 호르몬, 산소 요법)
  • 투여 경로별(주사, 경구, 흡입)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(주요 기업 5개사의 점유율)
• 시장 맵
  • 제품별
  • 투여 경로별
  • 유통 채널별
  • 지역별

제6장 북미의 알파1 항트립신 결핍 질환 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별
  • 투여 경로별
  • 유통 채널별
  • 국가별

제7장 유럽의 알파1 항트립신 결핍 질환 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별
  • 투여 경로별
  • 유통 채널별
  • 국가별

제8장 아시아태평양의 알파1 항트립신 결핍 질환 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별
  • 투여 경로별
  • 유통 채널별
  • 국가별

제9장 남미의 알파1 항트립신 결핍 질환 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 투여 경로별
  • 유통 채널별
  • 국가별

제10장 중동 및 아프리카의 알파1 항트립신 결핍 질환 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 투여 경로별
  • 유통 채널별
  • 국가별

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 전개
• 인수합병(M&A)
• 제품 발표

제13장 경쟁 구도

• Shire plc
• GlaxoSmithKline plc
• CSL Behring
• AstraZeneca Plc.
• Grifols S.A.
• Teva Pharmaceutical Industries
• Boehringer Ingelheim International GmbH
• Kamada Pharmaceuticals
• Pfizer Inc.
• Baxter International Inc.

제14장 전략적 제안

제15장 조사회사에 대해·면책사항

LSH

영문 목차

영문목차

The Global Alpha-1 Antitrypsin Deficiency Disease Market reached a valuation of USD 1809.36 Million in 2022, and it is poised for impressive growth throughout the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 6.49% up to 2028 and expected to reach USD 2627.18 Million by 2028. Alpha-1 Antitrypsin Deficiency (Alpha-1 Antitrypsin Deficiency Disease) is an uncommon genetic disorder impacting the lungs and liver. It arises due to insufficient levels of the alpha-1 antitrypsin protein, resulting in an elevated vulnerability to lung and liver diseases. Despite its rarity, Alpha-1 Antitrypsin Deficiency Disease significantly affects patients' quality of life and healthcare systems. As research advances and awareness spreads, the Alpha-1 Antitrypsin Deficiency Disease Market is undergoing changes, presenting both challenges and opportunities.

Alpha-1 antitrypsin is a liver-produced protein pivotal in safeguarding lungs against inflammation-induced damage from enzymes. In cases of Alpha-1 Antitrypsin Deficiency Disease, a genetic mutation leads to misfolded protein accumulation in the liver instead of release into the bloodstream. This deficiency heightens susceptibility to lung ailments like chronic obstructive pulmonary disease (COPD) and liver conditions such as cirrhosis.

While the Alpha-1 Antitrypsin Deficiency Disease market is relatively compact due to the disease's rarity, it garners attention from researchers, pharmaceutical firms, and healthcare providers. Notable players in diagnostics, treatments, and therapies concentrate on addressing the underlying deficiency and managing linked complications. Biotechnology, genomics, and personalized medicine progress yield targeted, effective treatments for Alpha-1 Antitrypsin Deficiency Disease, potentially revolutionizing patient outcomes.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 1809.36 Million
Market Size 2028	USD 2627.18 Million
CAGR 2023-2028	6.49%
Fastest Growing Segment	Alpha-1 Proteinase Inhibitor
Largest Market	North America

Government initiatives and research funding propel the global Alpha-1 Antitrypsin Deficiency Disease market. As rare disease awareness, like Alpha-1 Antitrypsin Deficiency Disease, heightens, policies and programs supporting research, diagnosis, and treatment development gain traction. Funds for research projects, clinical trials, and patient support captivate pharmaceutical companies and researchers, spurring accelerated advancements.

Primary Market Drivers

• 1. Increasing Patient Base: The Global Alpha-1 Antitrypsin Deficiency Disease Market witnesses substantial growth due to a rising patient population. Though a rare genetic disorder, underreported cases and misdiagnoses result in a larger target group as awareness and diagnostic precision improve. Heightened cases prompt increased pharmaceutical and research focus, driving market expansion.

• 2. Regulatory Backing: Collaborative efforts among researchers, clinicians, patients, advocacy groups, and pharmaceutical firms catalyze advancements in Alpha-1 Antitrypsin Deficiency Disease understanding, treatment, and patient care. Cross-institutional consortia, pharmaceutical-academic collaborations, and digital data sharing transform traditional research and treatment approaches, fostering progress.

Key Market Challenges

• 1. Underdiagnosis and Misdiagnosis: A substantial challenge in the Alpha-1 Antitrypsin Deficiency Disease market lies in its underdiagnosis and misdiagnosis. Many patients remain undiagnosed or misdiagnosed as other lung conditions, delaying accurate treatment strategies.

• 2. Limited Awareness: The rarity of Alpha-1 Antitrypsin Deficiency Disease results in limited awareness among the public and healthcare professionals, causing delayed diagnosis and insufficient support.

• 3. Complex Treatment: Developing effective treatments for Alpha-1 Antitrypsin Deficiency Disease is intricate due to its genetic nature and dual lung-liver complications, necessitating therapies addressing both aspects.

Key Market Trends

• 1. Technological Advancements: Technological breakthroughs in genetic screening enable early Alpha-1 Antitrypsin Deficiency Disease detection, allowing proactive intervention. Precision medicine tailors treatment based on genetic makeup, enhancing efficacy. Gene therapies and editing explore treating the genetic root, potentially transforming disease management.

• 2. Collaborative Efforts: Cross-disciplinary collaborations accelerate Alpha-1 Antitrypsin Deficiency Disease understanding and management. Research consortia, pharmaceutical-academic partnerships, and patient advocacy groups expedite research, innovation, and treatment development.

Segment Insights

• 1. Product: In 2022, the Alpha-1 Proteinase Inhibitor segment led the Alpha-1 Antitrypsin Deficiency Disease market and is expected to continue its growth trajectory. Replenishing deficient A1PI levels through enzyme replacement therapy (ERT) helps alleviate symptoms, slowing lung damage progression.

• 2. Distribution Channel: In 2022, Hospital pharmacies dominated the market, driven by the comprehensive care Alpha-1 Antitrypsin Deficiency Disease patients require, involving specialists from various disciplines.

Regional Insights

North America: This research hub boasts leading institutions, research centers, and pharmaceutical companies, propelling Alpha-1 Antitrypsin Deficiency Disease understanding, diagnostics, and treatments. Clinical trials predominantly occur here, giving early access to new therapies and consolidating North America's market leadership. The region's disposable income, healthcare spending, and coverage bolster market dominance.

Key Market Players

• Shire plc
• GlaxoSmithKline plc
• CSL Behring
• AstraZeneca Plc.
• Grifols S.A.
• Teva Pharmaceutical Industries
• Boehringer Ingelheim International GmbH
• Kamada Pharmaceuticals
• Pfizer Inc.
• Baxter International Inc.

Report Scope:

• In this report, the Global Alpha-1 Antitrypsin Deficiency Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Alpha-1 Antitrypsin Deficiency Disease Market, By Product:

• Alpha-1 Proteinase Inhibitor
• Bronchodilato
• Corticosteroid
• Oxygen Therapy

Alpha-1 Antitrypsin Deficiency Disease Market, By Route Of Administration:

• Injection
• Oral
• Inhalation

Alpha-1 Antitrypsin Deficiency Disease Market, By Distribution Channel:

• Hospitals Pharmacy
• Retail Pharmacies
• Online Pharmacies

Alpha-1 Antitrypsin Deficiency Disease Market, By Region:

• North America
• Asia-Pacific
• Europe
• Middle East & Africa
• South America

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Alpha-1 Antitrypsin Deficiency Disease Market.

Available Customizations:

• Global Alpha-1 Antitrypsin Deficiency Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Alpha-1 Proteinase Inhibitor, Bronchodilators, Corticosteroids, Oxygen Therapy)
  • 5.2.2. By Route Of Administration (Injection, Oral, Inhalation)
  • 5.2.3. By Distribution Channel (Hospitals Pharmacy, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (Shares of Top 5 Market Players)
• 5.3. Market Map
  • 5.3.1. By Product
  • 5.3.2. By Route of Administration
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
    • 6.2.4.1. United States Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.1.1. Market Size & Forecast
      • 6.2.4.1.1.1. By Value
      • 6.2.4.1.2. Market Share & Forecast
      • 6.2.4.1.2.1. By Product
      • 6.2.4.1.2.2. By Route of Administration
      • 6.2.4.1.2.3. By Distribution Channel (
    • 6.2.4.2. Canada Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.2.1. Market Size & Forecast
      • 6.2.4.2.1.1. By Value
      • 6.2.4.2.2. Market Share & Forecast
      • 6.2.4.2.2.1. By Product
      • 6.2.4.2.2.2. By Route of Administration
      • 6.2.4.2.2.3. By Distribution Channel
    • 6.2.4.3. Mexico Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.3.1. Market Size & Forecast
      • 6.2.4.3.1.1. By Value
      • 6.2.4.3.2. Market Share & Forecast
      • 6.2.4.3.2.1. By Test
      • 6.2.4.3.2.2. By Route of Administration
      • 6.2.4.3.2.3. By Distribution Channel

7. Europe Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
    • 7.2.4.1. France Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.1.1. Market Size & Forecast
      • 7.2.4.1.1.1. By Value
      • 7.2.4.1.2. Market Share & Forecast
      • 7.2.4.1.2.1. By Product
      • 7.2.4.1.2.2. By Route of Administration
      • 7.2.4.1.2.3. By Distribution Channel
    • 7.2.4.2. Germany Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.2.1. Market Size & Forecast
      • 7.2.4.2.1.1. By Value
      • 7.2.4.2.2. Market Share & Forecast
      • 7.2.4.2.2.1. By Product
      • 7.2.4.2.2.2. By Route of Administration
      • 7.2.4.2.2.3. By Distribution Channel
    • 7.2.4.3. United Kingdom Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.3.1. Market Size & Forecast
      • 7.2.4.3.1.1. By Value
      • 7.2.4.3.2. Market Share & Forecast
      • 7.2.4.3.2.1. By Product
      • 7.2.4.3.2.2. By Route of Administration
      • 7.2.4.3.2.3. By Distribution Channel
    • 7.2.4.4. Italy Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.4.1. Market Size & Forecast
      • 7.2.4.4.1.1. By Value
      • 7.2.4.4.2. Market Share & Forecast
      • 7.2.4.4.2.1. By Product
      • 7.2.4.4.2.2. By Route of Administration
      • 7.2.4.4.2.3. By Distribution Channel
    • 7.2.4.5. Spain Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.5.1. Market Size & Forecast
      • 7.2.4.5.1.1. By Value
      • 7.2.4.5.2. Market Share & Forecast
      • 7.2.4.5.2.1. By Product
      • 7.2.4.5.2.2. By Route of Administration
      • 7.2.4.5.2.3. By Distribution Channel

8. Asia Pacific Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
    • 8.2.4.1. China Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.1.1. Market Size & Forecast
      • 8.2.4.1.1.1. By Value
      • 8.2.4.1.2. Market Share & Forecast
      • 8.2.4.1.2.1. By Product
      • 8.2.4.1.2.2. By Route of Administration
      • 8.2.4.1.2.3. By Distribution Channel
    • 8.2.4.2. India Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.2.1. Market Size & Forecast
      • 8.2.4.2.1.1. By Value
      • 8.2.4.2.2. Market Share & Forecast
      • 8.2.4.2.2.1. By Product
      • 8.2.4.2.2.2. By Route of Administration
      • 8.2.4.2.2.3. By Distribution Channel
    • 8.2.4.3. South Korea Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.3.1. Market Size & Forecast
      • 8.2.4.3.1.1. By Value
      • 8.2.4.3.2. Market Share & Forecast
      • 8.2.4.3.2.1. By Product
      • 8.2.4.3.2.2. By Route of Administration
      • 8.2.4.3.2.3. By Distribution Channel
    • 8.2.4.4. Japan Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.4.1. Market Size & Forecast
      • 8.2.4.4.1.1. By Value
      • 8.2.4.4.2. Market Share & Forecast
      • 8.2.4.4.2.1. By Product
      • 8.2.4.4.2.2. By Route of Administration
      • 8.2.4.4.2.3. By Distribution Channel
    • 8.2.4.5. Australia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.5.1. Market Size & Forecast
      • 8.2.4.5.1.1. By Value
      • 8.2.4.5.2. Market Share & Forecast
      • 8.2.4.5.2.1. By Product
      • 8.2.4.5.2.2. By Route of Administration
      • 8.2.4.5.2.3. By Distribution Channel

9. South America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
    • 9.2.4.1. Brazil Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.1.1. Market Size & Forecast
      • 9.2.4.1.1.1. By Value
      • 9.2.4.1.2. Market Share & Forecast
      • 9.2.4.1.2.1. By Product
      • 9.2.4.1.2.2. By Route of Administration
      • 9.2.4.1.2.3. By Distribution Channel
    • 9.2.4.2. Argentina Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.2.1. Market Size & Forecast
      • 9.2.4.2.1.1. By Value
      • 9.2.4.2.2. Market Share & Forecast
      • 9.2.4.2.2.1. By Product
      • 9.2.4.2.2.2. By Route of Administration
      • 9.2.4.2.2.3. By Distribution Channel
    • 9.2.4.3. Colombia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.3.1. Market Size & Forecast
      • 9.2.4.3.1.1. By Value
      • 9.2.4.3.2. Market Share & Forecast
      • 9.2.4.3.2.1. By Product
      • 9.2.4.3.2.2. By Route of Administration
      • 9.2.4.3.2.3. By Distribution Channel

10. Middle East & Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
    • 10.2.4.1. South Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.1.1. Market Size & Forecast
      • 10.2.4.1.1.1. By Value
      • 10.2.4.1.2. Market Share & Forecast
      • 10.2.4.1.2.1. By Product
      • 10.2.4.1.2.2. By Route of Administration
      • 10.2.4.1.2.3. By Distribution Channel
    • 10.2.4.2. Saudi Arabia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.2.1. Market Size & Forecast
      • 10.2.4.2.1.1. By Value
      • 10.2.4.2.2. Market Share & Forecast
      • 10.2.4.2.2.1. By Product
      • 10.2.4.2.2.2. By Route of Administration
      • 10.2.4.2.2.3. By Distribution Channel
    • 10.2.4.3. UAE Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.3.1. Market Size & Forecast
      • 10.2.4.3.1.1. By Value
      • 10.2.4.3.2. Market Share & Forecast
      • 10.2.4.3.2.1. By Product
      • 10.2.4.3.2.2. By Route of Administration
      • 10.2.4.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. Shire plc
• 13.2. GlaxoSmithKline plc
• 13.3. CSL Behring
• 13.4. AstraZeneca Plc.
• 13.5. Grifols S.A.
• 13.6. Teva Pharmaceutical Industries
• 13.7. Boehringer Ingelheim International GmbH
• 13.8. Kamada Pharmaceuticals
• 13.9. Pfizer Inc.
• 13.10. Baxter International Inc.

14. Strategic Recommendations

15. About us & Disclaimer

관련자료